ICERWATCH PUBLIC COMMENTS

New Series: THE LAST WORD

As part of the Patient Access and Affordability Project's ongoing work to hold ICER accountable, we are pleased to announce a new report series, "The Last Word." In this series, Dr. Paul Langley dissects and refutes the conclusions in ICER's most recent Final Evidence...

read more
Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.

Comments on ICER’s February 11th Draft Evidence Report, “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma.

Comments on ICER's February 11, 2021 Draft Evidence Report “Anti B-Cell Maturation Antigen CAR T-cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma”.  Some of the concerns raised in the letter point out that the...

read more